178 related articles for article (PubMed ID: 35172988)
1. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
Welsh RC; Dehghani P; Lopes R; Wojdyla DM; Aronson R; Granger CB; Windecker S; Vora AN; Vinereanu D; Halvorsen S; Parkhomenko A; Mehran R; Alexander JH; Goodman S
Open Heart; 2022 Feb; 9(1):. PubMed ID: 35172988
[TBL] [Abstract][Full Text] [Related]
2. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
[TBL] [Abstract][Full Text] [Related]
4. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Hijazi Z; Alexander JH; Li Z; Wojdyla DM; Mehran R; Granger CB; Parkhomenko A; Bahit MC; Windecker S; Aronson R; Berwanger O; Halvorsen S; de Waha-Thiele S; Sinnaeve P; Darius H; Storey RF; Lopes RD
Circulation; 2021 Mar; 143(12):1215-1223. PubMed ID: 33461308
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
Lopes RD; Heizer G; Aronson R; Vora AN; Massaro T; Mehran R; Goodman SG; Windecker S; Darius H; Li J; Averkov O; Bahit MC; Berwanger O; Budaj A; Hijazi Z; Parkhomenko A; Sinnaeve P; Storey RF; Thiele H; Vinereanu D; Granger CB; Alexander JH;
N Engl J Med; 2019 Apr; 380(16):1509-1524. PubMed ID: 30883055
[TBL] [Abstract][Full Text] [Related]
6. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
Bahit MC; Vora AN; Li Z; Wojdyla DM; Thomas L; Goodman SG; Aronson R; Jordan JD; Kolls BJ; Dombrowski KE; Vinereanu D; Halvorsen S; Berwanger O; Windecker S; Mehran R; Granger CB; Alexander JH; Lopes RD
JAMA Cardiol; 2022 Jul; 7(7):682-689. PubMed ID: 35612866
[TBL] [Abstract][Full Text] [Related]
7. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.
Harskamp RE; Fanaroff AC; Lopes RD; Wojdyla DM; Goodman SG; Thomas LE; Aronson R; Windecker S; Mehran R; Granger CB; Alexander JH
J Am Coll Cardiol; 2022 Feb; 79(5):417-427. PubMed ID: 35115097
[TBL] [Abstract][Full Text] [Related]
9. [Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Darius H
Dtsch Med Wochenschr; 2020 Jul; 145(14):978-986. PubMed ID: 32668469
[TBL] [Abstract][Full Text] [Related]
10. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.
Potpara TS; Mujovic N; Proietti M; Dagres N; Hindricks G; Collet JP; Valgimigli M; Heidbuchel H; Lip GYH
Europace; 2020 Jan; 22(1):33-46. PubMed ID: 31603196
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
Rivolo S; Di Fusco M; Polanco C; Kang A; Dhanda D; Savone M; Skandamis A; Kongnakorn T; Soto J
PLoS One; 2021; 16(11):e0259251. PubMed ID: 34767564
[TBL] [Abstract][Full Text] [Related]
12. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Vranckx P; Valgimigli M; Eckardt L; Tijssen J; Lewalter T; Gargiulo G; Batushkin V; Campo G; Lysak Z; Vakaliuk I; Milewski K; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Goette A
Lancet; 2019 Oct; 394(10206):1335-1343. PubMed ID: 31492505
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium.
Kongnakorn T; Lanitis T; Lieven A; Thijs V; Marbaix S
Clin Drug Investig; 2014 Oct; 34(10):709-21. PubMed ID: 25164005
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
Gargiulo G; Cannon CP; Gibson CM; Goette A; Lopes RD; Oldgren J; Korjian S; Windecker S; Esposito G; Vranckx P; Valgimigli M
Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f50-f60. PubMed ID: 33119069
[TBL] [Abstract][Full Text] [Related]
15. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
Kopin D; Jones WS; Sherwood MW; Wojdyla DM; Wallentin L; Lewis BS; Verheugt FWA; Vinereanu D; Bahit MC; Halvorsen S; Huber K; Parkhomenko A; Granger CB; Lopes RD; Alexander JH
Am Heart J; 2018 Mar; 197():133-141. PubMed ID: 29447773
[TBL] [Abstract][Full Text] [Related]
16. The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Fanaroff AC; Lopes RD
Prog Cardiovasc Dis; 2021; 69():11-17. PubMed ID: 34883097
[TBL] [Abstract][Full Text] [Related]
17. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
Connors JM; Brooks MM; Sciurba FC; Krishnan JA; Bledsoe JR; Kindzelski A; Baucom AL; Kirwan BA; Eng H; Martin D; Zaharris E; Everett B; Castro L; Shapiro NL; Lin JY; Hou PC; Pepine CJ; Handberg E; Haight DO; Wilson JW; Majercik S; Fu Z; Zhong Y; Venugopal V; Beach S; Wisniewski S; Ridker PM;
JAMA; 2021 Nov; 326(17):1703-1712. PubMed ID: 34633405
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation.
Gaubert M; Resseguier N; Laine M; Bonello L; Camoin-Jau L; Paganelli F
J Thromb Haemost; 2018 Mar; 16(3):465-473. PubMed ID: 29274198
[TBL] [Abstract][Full Text] [Related]
19. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
[TBL] [Abstract][Full Text] [Related]
20. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.
Lopes RD; Leonardi S; Wojdyla DM; Vora AN; Thomas L; Storey RF; Vinereanu D; Granger CB; Goodman SG; Aronson R; Windecker S; Thiele H; Valgimigli M; Mehran R; Alexander JH
Circulation; 2020 Mar; 141(9):781-783. PubMed ID: 31707833
[No Abstract] [Full Text] [Related]
[Next] [New Search]